Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
“Our team has demonstrated the presence of SETDB1 abnormalities, particularly its amplification, through WES analysis of osteosarcoma human samples and cell lines” “Our team has demonstrated the ...
OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation For OST-HER2 In The Treatment Of Pulmonary Recurrence In Resected Osteosarcoma. OS Therapies Granted EMA's Advanced ...
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction of ...
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient's immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its ...
(RTTNews) - GSK plc (GSK), a pharmaceutical and biotechnology company, on Tuesday announced that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for GSK'227, ...
The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent insights highlight the intricate interplay between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results